India Glycols Limited has informed the Exchange about Investor Presentation
INDIAGLYCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
India Glycols reported strong Q1 FY26 results with consolidated net revenue up 7.4% YoY at ₹1,040 Cr, driven by 45.4% growth in Bio-Fuel (₹348 Cr) and 22.4% growth in Potable Spirits (₹342 Cr). EBITDA rose 17.7% to ₹151 Cr with margin expanding 128 bps to 14.5%, and PAT grew 21.3% to ₹73 Cr with margin at 7.0%. Segment-wise, PS EBIT margins surged from 17.5% to 21.1% and BSPC margins improved 100 bps to 10.9%, while Ennature Biopharma saw sharp margin compression to 2.4%. The company detailed its proposed demerger into three listed entities (IGL for chemicals, IGL Spirits for PS & Bio-Fuel, and Ennature Bio Pharma for biopharma) and announced a 1:2 stock split with record date of 12th August 2025.
Positive near-term sentiment from broad-based margin expansion and strong Bio-Fuel/PS growth, though Biopharma remains a drag. The proposed three-way demerger could unlock value by giving each business a focused identity, but execution risk and regulatory approvals remain key overhangs. Stock split improves liquidity for retail investors.